Company Profile
Regeneron Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- REGN
- Exchange:
- NASDAQ
- Sector:
- Antibody Drugs, Biopharma
- Location:
- United States
Stock performance
667.17 USD (+1.70%)
Close
Last updated: July 27, 2026
63.2B USD
Market cap
Why the stock is moving
As of Jul 27, 2026, REGN closed up 1.70% at $667.17. No new same-company headline was identified in the current news window.
Company overview
Business overview
Regeneron is a biotechnology company built around antibody discovery, biologics development, and marketed therapies across eye disease, immunology, and oncology. The company’s platform and R&D engine make it one of the most scientifically respected names in public biotech.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Regeneron has a strong U.S. base and global commercial reach. It sits squarely in high-quality biotechnology with a platform-driven identity.
Business Model Characteristics
Regeneron combines product revenue with a deep internal discovery engine and repeatable biologics development. Investors track existing product performance, pipeline breadth, and the ability of the antibody platform to keep producing new growth opportunities.
Position Within the Biotechnology Landscape
Regeneron occupies a premium position in biotech because it has both commercial scale and a durable R&D platform. Compared with smaller clinical-stage names, it is less binary, but data, label, and partnership events still move the stock.
Future catalysts
Regeneron’s next watchpoints are cemdisiran’s regulatory path, geographic-atrophy and PNH work, and the broader antibody-platform execution. The next checkpoint matters because it tells investors whether the program is still moving on schedule or whether the timeline needs to be reset. A clean outcome also makes it easier to think about the next regulatory or label step instead of just the current filing.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
LEGN · Source: Legend Biotech Corporation
- 03
- 04
- 05
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Regeneron Pharmaceuticals (REGN)?
Regeneron Pharmaceuticals (REGN) most recently closed at 667.17 USD, a +1.70% move versus the previous session.
What is the market cap of Regeneron Pharmaceuticals (REGN)?
Regeneron Pharmaceuticals currently has a market capitalization of 63.2B USD on BioPharmSignal.
What does Regeneron Pharmaceuticals do?
Regeneron is a biotechnology company built around antibody discovery, biologics development, and marketed therapies across eye disease, immunology, and oncology. The company’s platform and R&D engine make it one of the most scientifically respected names in public biotech.
On which exchange is REGN stock listed?
Regeneron Pharmaceuticals (REGN) is associated with NASDAQ, United States, Antibody Drugs, Biopharma.
What is Regeneron?
Regeneron’s next watchpoints are cemdisiran’s regulatory path, geographic-atrophy and PNH work, and the broader antibody-platform execution.
Which conditions is Regeneron Pharmaceuticals targeting with Regeneron?
Regeneron Pharmaceuticals is associated with oncology, immunology based on its company overview and current catalyst commentary.
How does Regeneron Pharmaceuticals describe recent progress with Regeneron?
Regeneron’s next watchpoints are cemdisiran’s regulatory path, geographic-atrophy and PNH work, and the broader antibody-platform execution.
What future catalysts are investors watching for Regeneron Pharmaceuticals?
Regeneron’s next watchpoints are cemdisiran’s regulatory path, geographic-atrophy and PNH work, and the broader antibody-platform execution. The next checkpoint matters because it tells investors whether the program is still moving on schedule or whether the timeline needs to be reset. A clean outcome also makes it easier to think about the next regulatory...